ADHD Medication Abuse Risks Compared in Global Study
New research shows how often specific ADHD treatments are linked to reports of abuse and dependence.
Updated on Sept. 22, 2026 in Substance Abuse
Live Poll
Do you trust that common ADHD medications have comparable risks for abuse and dependence?
Researchers analyzed over 55,000 international safety reports to compare the potential for abuse and dependence among common ADHD medications. The findings highlight the relative risks for patients, particularly those between 15 and 25 years old.
Why it matters
Understanding the real-world abuse profile of ADHD treatments helps clinicians and patients weigh safety risks when selecting medication. This study provides critical data on how different drugs compare in clinical settings where abuse or dependence is reported.
A disproportionality analysis of 55,219 VigiBase reports found that lisdexamfetamine and methylphenidate show comparable abuse and dependence risks. Atomoxetine demonstrated the lowest relative reporting odds, while bupropion was associated with 47.13% of all identified cases.
The players
General Psychiatry
A medical journal that publishes peer-reviewed research on mental health and psychiatric conditions.
World Health Organization
The international agency responsible for managing the VigiBase pharmacovigilance database.
The details
The study utilized a case-noncase disproportionality approach to assess safety signals within the WHO VigiBase database. Researchers calculated reporting odds ratios adjusted for factors including patient age, sex, and report seriousness. By evaluating these signals, the study isolated how often these drugs were linked to abuse versus other reported adverse events, revealing that most cases (89.29%) were categorized as serious.
Timeline
September 22, 2026: The study was published in General Psychiatry.
Health Landscape
Comparative, real-world evidence for the abuse potential of medications used to treat ADHD has historically been limited. By leveraging the WHO VigiBase global safety database, this study provides a crucial update to the current understanding of psychiatric medication safety profiles.
If you or a family member are using ADHD medications, it is worth discussing these comparative risk profiles with your doctor. Always report any concerns regarding medication dependence or side effects to your healthcare provider immediately.
The takeaway
This analysis reveals that while abuse reports vary significantly by medication type, lisdexamfetamine and methylphenidate present similar safety signals. Patients should track any changes in how they feel while on medication and consult their physician about the safest treatment options.
Further reading
For more information on managing substance risks and treatment safety, visit Substance Abuse.
Source note: This article includes information reported by Psychiatry Advisor.
Live Poll
Do you trust that common ADHD medications have comparable risks for abuse and dependence?
